{
    "title": "112_hr6160",
    "content": "The Act titled \"Stop Tampering of Prescription Pills Act of 2012\" mandates the use of tamper-resistant technology. The \"Stop Tampering of Prescription Pills Act of 2012\" requires tamper-resistant drugs to contain controlled substances classified as opium or its derivatives, formulated for oral administration, and exhibit properties that make manipulation difficult for misuse or abuse. The \"Stop Tampering of Prescription Pills Act of 2012\" mandates tamper-resistant drugs to have properties that deter misuse or abuse, including additional ingredients with demonstrated effectiveness in preventing abuse. Application for approval of brand name drugs must include necessary information to show compliance with tamper-resistant requirements. The \"Stop Tampering of Prescription Pills Act of 2012\" requires tamper-resistant properties for brand name drugs, including specific criteria for approval of new drugs containing controlled substances. The \"Stop Tampering of Prescription Pills Act of 2012\" mandates tamper-resistant features for brand name drugs, with criteria for approval of new drugs containing controlled substances. Section 505(j) of the Federal Food, Drug, and Cosmetic Act is amended to address issues such as drug shortages and public health needs. The Cosmetic Act is amended to include criteria for tamper-resistant drugs, requiring evidence of resistance to manipulation comparable to listed drugs. The Cosmetic Act is amended to include criteria for tamper-resistant drugs, requiring evidence of resistance to manipulation comparable to listed drugs. In subparagraph (C), it is specified that the listed drug must be tamper-resistant and have active moieties that differ in any material respect from those of the new drug. The Cosmetic Act is amended to include criteria for tamper-resistant drugs. If a drug approved under an application becomes tamper-resistant, it must meet specific requirements to be considered bioequivalent to the listed drug. The Cosmetic Act is amended to include criteria for tamper-resistant drugs. A withdrawal or suspension of a drug formulated for oral administration is considered for safety or effectiveness reasons if certain conditions are met. The Federal Food, Drug, and Cosmetic Act is amended to include criteria for the withdrawal of previously approved brand name and generic drugs containing controlled substances classified as opium, opiates, or derivatives. The drugs must be formulated for oral administration, not tamper-resistant, and have not been discontinued from marketing. The Federal Food, Drug, and Cosmetic Act is amended to include criteria for the withdrawal of previously approved brand name and generic drugs containing controlled substances classified as opium, opiates, or derivatives. The Secretary may waive certain requirements for drugs intended for special needs populations. The effective date of withdrawal for a drug can be delayed to allow the sponsor to obtain approval for a tamper-resistant formulation. The Federal Food, Drug, and Cosmetic Act is amended to include criteria for the withdrawal of drugs found to be tamper-resistant. The Secretary will update the list of tamper-resistant drugs as needed."
}